Alpine Immune Sciences Inc (ALPN.OQ)

ALPN.OQ on NASDAQ Stock Exchange Global Market

19 Jan 2018
Change (% chg)

$0.45 (+4.23%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Alpine Immune Sciences qtrly earnings per share ‍$0.18​
Tuesday, 14 Nov 2017 

Nov 13 (Reuters) - Alpine Immune Sciences Inc ::Alpine Immune Sciences reports corporate update and third quarter 2017 financial results.Q3 revenue $100,000 versus $700,000.Alpine Immune Sciences Inc - ‍company expects to have cash to fund operations into 2020​.Alpine Immune Sciences Inc qtrly earnings per share ‍$0.18​.  Full Article

Nivalis Q2 loss per share $0.55
Tuesday, 2 Aug 2016 

Nivalis Therapeutics Inc : Q2 loss per share $0.55 . Nivalis therapeutics reports second quarter 2016 financial results .Q2 earnings per share view $-0.52 -- Thomson Reuters I/B/E/S.  Full Article

Nivalis Therapeutics files for mixed shelf of up to $142.5 mln - SEC filing
Wednesday, 6 Jul 2016 

Nivalis Therapeutics Inc : Says files for mixed shelf of up to $142.5 million - SEC filing Source:(http://bit.ly/29xPQCz ) Further company coverage: [NVLS.O] (Bengaluru Newsroom: +1 646 223 8780).  Full Article

Nivalis Therapeutics, Inc reports FDA fast track designation for n91115
Friday, 19 Feb 2016 

Nivalis Therapeutics, Inc:Announces FDA fast track designation for n91115 in patients with cystic fibrosis.Says company expects data from this trial in the second half of 2016.  Full Article